Search

Your search keyword '"Pizzocaro G"' showing total 336 results
Start Over Author "Pizzocaro G"
336 results on '"Pizzocaro G"'

1. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study

Author

Necchi, A., Mariani, L., Di Nicola, M., Lo Vullo, S., Nicolai, N., Giannatempo, P., Raggi, D., Farè, E., Magni, M., Piva, L., Matteucci, P., Catanzaro, M., Biasoni, D., Torelli, T., Stagni, S., Bengala, C., Barone, C., Schiavetto, I., Siena, S., Carlo-Stella, C., Pizzocaro, G., Salvioni, R., and Gianni, A.M.

Published
2015
Full Text
View/download PDF

5. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)

Author

Schmoll, H.J., Souchon, R., Krege, S., Albers, P., Beyer, J., Kollmannsberger, C., Fossa, S.D., Skakkebaek, N.E., de Wit, R., Fizazi, K., Droz, J.P., Pizzocaro, G., Daugaard, G., de Mulder, P.H.M., Horwich, A., Oliver, T., Huddart, R., Rosti, G., Paz Ares, L., Pont, O., Hartmann, J.T., Aass, N., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Classen, J., Clemm, S., Culine, S., de Wit, M., Derigs, H.G., Dieckmann, K.P., Flasshove, M., Garcia del Muro, X., Gerl, A., Germa-Lluch, J.R., Hartmann, M., Heidenreich, A., Hoeltl, W., Joffe, J., Jones, W., Kaiser, G., Klepp, O., Kliesch, S., Kisbenedek, L., Koehrmann, K.U., Kuczyk, M., Laguna, M.P., Leiva, O., Loy, V., Mason, M.D., Mead, G.M., Mueller, R.P., Nicolai, N., Oosterhof, G.O.N., Pottek, T., Rick, O., Schmidberger, H., Sedlmayer, F., Siegert, W., Studer, U., Tjulandin, S., von der Maase, H., Walz, P., Weinknecht, S., Weissbach, L., Winter, E., and Wittekind, C.

Published
2004
Full Text
View/download PDF

17. Cancer of the Testis

Author

Pizzocaro, G., Veronesi, Umberto, editor, Arnesjø, Bo, editor, Burn, Ian, editor, Denis, Louis, editor, and Mazzeo, Francesco, editor

Published
1989
Full Text
View/download PDF

18. Laparoscopic retroperitoneal lymph-node dissection (L-RPLND) is not only a staging procedure in stage I non-seminomatous germ-cell testicular tumors (NSGCTT): Mature data from a referral centre

Author

Nicolai, N., primary, Tarabelloni, N., additional, Catanzaro, M., additional, Gasperoni, F., additional, Stagni, S., additional, Torelli, T., additional, Tesone, A., additional, Kungulli, A., additional, Necchi, A., additional, Giannatempo, P., additional, Raggi, D., additional, Colecchia, M., additional, Salvioni, R., additional, Piva, L., additional, Pizzocaro, G., additional, and Biasoni, D., additional

Published
2017
Full Text
View/download PDF

20. IGG practice guidelines on germ cell tumor in adult male patients

Author

De Giorgi U, Nicolai N, Tana S, Tavolini IM, Palazzi S, Bracarda S, Tedeschi L, Frassineti L, Da Pozzo L, Pastorino U, Emiliani E, Marangolo M, Pizzocaro G, Rosti G, Salvioni R, Italian Germ cell cancer G.r.o.u.p., PALMIERI, GIOVANNELLA, De Giorgi, U, Nicolai, N, Tana, S, Tavolini, Im, Palazzi, S, Bracarda, S, Tedeschi, L, Palmieri, Giovannella, Frassineti, L, Da Pozzo, L, Pastorino, U, Emiliani, E, Marangolo, M, Pizzocaro, G, Rosti, G, Salvioni, R, and Italian Germ cell cancer, G. r. o. u. p.

Published
2008

23. 57 Neo-adjuvant and adjuvant combination of a taxane plus cisplatin and 5-fluorouracil in patients undergoing lymph-node dissection for nodal metastases from squamous cell carcinoma (SCC) of the penis: Is there an indication for a recommendable use?

Author

Nicolai, N., primary, Sangalli, L.M., additional, Necchi, A., additional, Giannatempo, P., additional, Paganoni, A.M., additional, Colecchia, M., additional, Piva, L., additional, Catanzaro, M., additional, Biasoni, D., additional, Stagni, S., additional, Torelli, T., additional, Raggi, D., additional, Faré, E., additional, Crestani, A., additional, Pizzocaro, G., additional, and Salvioni, R., additional

Published
2014
Full Text
View/download PDF

24. Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes

Author

Necchi, A., primary, Nicolai, N., additional, Mariani, L., additional, Raggi, D., additional, Farè, E., additional, Giannatempo, P., additional, Catanzaro, M., additional, Biasoni, D., additional, Torelli, T., additional, Stagni, S., additional, Milani, A., additional, Piva, L., additional, Pizzocaro, G., additional, Gianni, A.M., additional, and Salvioni, R., additional

Published
2013
Full Text
View/download PDF

28. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

Author

Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Cavallin-Stahl, E., Classen, J., Clemm, C., Cohn-Cedermark, G., Culine, S., Daugaard, G., Mulder, P.H.M. de, Santis, M. de, Wit, M. de, Wit, R. de, Derigs, H.G., Dieckmann, K.P., Dieing, A., Droz, J.P., Fenner, M., Fizazi, K., Flechon, A., Fossa, S.D., Muro, X.G. del, Gauler, T., Geczi, L., Gerl, A., Germa-Lluch, J.R., Gillessen, S., Hartmann, J.T., Hartmann, M., Heidenreich, A., Hoeltl, W., Horwich, A., Huddart, R., Jewett, M., Joffe, J., Jones, W., Kisbenedek, L., Klepp, O., Kliesch, S., Koehrmann, K.U., Kollmannsberger, C., Kuczyk, M.A., Laguna, P.M., Galvis, O.L., Loy, V., Mason, M.D., Mead, G.M., Mueller, R., Nichols, C., Nicolai, N., Oliver, T., Ondrus, D., Oosterhof, G.O.N., Paz-Ares, L., Pizzocaro, G., Pont, J.J.H.H.M. de, Pottek, T., Powles, T., Rick, O., Rosti, G., Salvioni, R., Scheiderbauer, J., Schmelz, H.U., Schmidberger, H., Schmoll, H.J., Schrader, M., Sedlmayer, F., Skakkebaek, N.E., Sohaib, A., Tjulandin, S., Warde, P., Weinknecht, S., Weissbach, L., Wittekind, C., Winter, E., Wood, L., Maase, H. von der, Krege, S., Beyer, J., Souchon, R., Albers, P., Albrecht, W., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Cavallin-Stahl, E., Classen, J., Clemm, C., Cohn-Cedermark, G., Culine, S., Daugaard, G., Mulder, P.H.M. de, Santis, M. de, Wit, M. de, Wit, R. de, Derigs, H.G., Dieckmann, K.P., Dieing, A., Droz, J.P., Fenner, M., Fizazi, K., Flechon, A., Fossa, S.D., Muro, X.G. del, Gauler, T., Geczi, L., Gerl, A., Germa-Lluch, J.R., Gillessen, S., Hartmann, J.T., Hartmann, M., Heidenreich, A., Hoeltl, W., Horwich, A., Huddart, R., Jewett, M., Joffe, J., Jones, W., Kisbenedek, L., Klepp, O., Kliesch, S., Koehrmann, K.U., Kollmannsberger, C., Kuczyk, M.A., Laguna, P.M., Galvis, O.L., Loy, V., Mason, M.D., Mead, G.M., Mueller, R., Nichols, C., Nicolai, N., Oliver, T., Ondrus, D., Oosterhof, G.O.N., Paz-Ares, L., Pizzocaro, G., Pont, J.J.H.H.M. de, Pottek, T., Powles, T., Rick, O., Rosti, G., Salvioni, R., Scheiderbauer, J., Schmelz, H.U., Schmidberger, H., Schmoll, H.J., Schrader, M., Sedlmayer, F., Skakkebaek, N.E., Sohaib, A., Tjulandin, S., Warde, P., Weinknecht, S., Weissbach, L., Wittekind, C., Winter, E., Wood, L., and Maase, H. von der

Abstract

Item does not contain fulltext, OBJECTIVES: The first consensus report that had been presented by the European Germ Cell Cancer Consensus Group (EGCCCG) in 2004 has found widespread approval by many colleagues throughout the world. In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, The Netherlands. METHODS: Medical oncologists, urologic surgeons, radiation oncologists as well as pathologists from several European countries reviewed and discussed the data that had emerged since the 2002 conference and incorporated the new data into updated and revised guidelines. As for the first meeting the methodology of evidence-based medicine (EBM) was applied. The results of the discussion were compiled by the writing committee. All participants have agreed to this final update. RESULTS: The second part of the consensus paper includes the treatment of metastasised disease, residual tumour resection, salvage therapy, follow-up, and late toxicities. CONCLUSIONS: Whereas the vast majority of the recommendations made in 2004 remain valid 3 yr later, refinements in the treatment of early-stage as well as of advanced-stage testicular cancer have emerged from clinical trials. Despite technical improvements, expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer. In addition, the particular needs of testicular cancer survivors have been acknowledged.

Published
2008

29. Case report: renal cell carcinoma presenting as hypertension in pregnancy

Author

Buda, A, Pizzocaro, G, Ceruti, P, Salvioni, R, Battistello, M, Vergani, P, VERGANI, PATRIZIA, Buda, A, Pizzocaro, G, Ceruti, P, Salvioni, R, Battistello, M, Vergani, P, and VERGANI, PATRIZIA

Abstract

Renal cell carcinoma is a rare, potentially fatal tumor that occasionally occurs during pregnancy. The probability of cure is directly related to the stage or degree of tumor dissemination. Surgical resection is the mainstay of treatment of this disease. A case of patient who was diagnosed with a renal mass in the second trimester of pregnancy is reported. She underwent left radical nephrectomy at 17 weeks' gestation.

Published
2008

30. 1055 Modified cisplatin, etoposide and ifosfamide (PEI) salvage therapy for male germ-cell tumors (GCT). Long-term efficacy and safety outcomes

Author

Necchi, A., primary, Mariani, L., additional, Nicolai, N., additional, Raggi, D., additional, Farè, E., additional, Giannatempo, P., additional, Piva, L., additional, Biasoni, D., additional, Catanzaro, M., additional, Torelli, T., additional, Stagni, S., additional, Pizzocaro, G., additional, Gianni, A., additional, and Salvioni, R., additional

Published
2013
Full Text
View/download PDF

31. 83 Long-term efficacy and safety outcomes of the modified (simplified) combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) as front-line therapy for unresectable or metastatic urothelial cancer (UC)

Author

Necchi, A., primary, Mariani, L., additional, Giannatempo, P., additional, Raggi, D., additional, Fare', E., additional, Pizzocaro, G., additional, Piva, L., additional, Biasoni, D., additional, Torelli, T., additional, Catanzaro, M., additional, Stagni, S., additional, Milani, A., additional, Gianni, A., additional, De Braud, F., additional, Nicolai, N., additional, and Salvioni, R., additional

Published
2013
Full Text
View/download PDF

32. International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers

Author

Mead, GM, Stenning, SP, Cook, P, Fossa, SD, Horwich, A, Kaye, SB, Oliver, RTD, deMulder, PHM, deWit, R, Stoter, G, Sylvester, RJ, Bajorin, DF, Bosl, GJ, Mazumdar, M, Nichols, CR, Amato, R, Pizzocaro, G, Droz, JP, Kramar, A, Daugaard, G, CortesFunes, H, PazAres, L, Levi, JA, Colls, BM, Harvey, VJ, Coppin, C, and Faculteit Medische Wetenschappen/UMCG

Subjects
TESTICULAR CANCER, HIGH-DOSE CHEMOTHERAPY, GROUP PROTOCOL, COMBINATION CHEMOTHERAPY, MANAGEMENT, TRIAL, BONE-MARROW TRANSPLANTATION, BLEOMYCIN, POOR-RISK, TUMORS
Abstract

Purpose: Cisplatin-containing chemotherapy has dramatically improved the outlook for patients with metastatic germ cell tumors (GCT), and overall cure rates now exceed 80%. To make appropriate risk-based decisions about therapy and to facilitate collaborative trials, a simple prognostic factor-based staging classification is required. Materials: Collaborative groups from 10 countries provided clinical data on patients with metastatic GCT treated with cisplatin-containing chemotherapy. Multivariate analyses of prognostic factors for progression and survival were performed and models were validated on on independent data set. Results: Data were available on 5,202 patients with nonseminomatous GCT (NSGCT) and 660 patients with seminoma. Median follow-up time was 5 years, For NSGCT the following independent adverse factors were identified: mediastinal primary site; degree of elevation of alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactic dehydrogenase (LDH); and presence of nonpulmonary visceral metastases (NPVM), such as liver, bone, and brain. For seminoma, the predominant adverse feature was the presence of NPVM. integration of these factors produced the following groupings: good prognosis, comprising 60% of GCT with a 91% (89% to 93%) 5-year survival rate; intermediate prognosis, comprising 26% of GCT with a 79% (75% to 83%) 5-year survival rate; and poor prognosis, comprising 14% of GCT (all with NSGCT) with a 48% (42% to 54%) 5-year survival rate. Conclusion: An easily applicable, clinically based, prognostic classification for GCT has been agreed on between all the major clinical trial groups who are presently active worldwide. This should be used in clinical practice and in the design and reporting of clinical trials to aid international collaboration and understanding. (C) 1997 by American Society of Clinical Oncology.

Published
1997

44. Pros and Cons of Retroperitoneal Lymphadenectomy in Operable Renal Cell Carcinoma

Author

Pizzocaro G and Piva L

Subjects
medicine.medical_specialty, Kidney, business.industry, Urology, medicine.medical_treatment, cons, medicine.disease, Kidney Neoplasms, Surgery, medicine.anatomical_structure, Renal cell carcinoma, Lymphatic Metastasis, medicine, Grawitz tumor, Humans, Lymph Node Excision, Lymphadenectomy, Retroperitoneal Neoplasms, Radiology, business, Retroperitoneal lymphadenectomy, Carcinoma, Renal Cell
Published
1990

45. Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study

Author

Facendola, G, primary, Locatelli, MC, additional, Pizzocaro, G, additional, Piva, L, additional, Pegoraro, C, additional, Pallavicini, EB, additional, Signaroldi, A, additional, Meregalli, M, additional, Lombardi, F, additional, Beretta, GD, additional, Scanzi, F, additional, Labianca, R, additional, and Luporini, G, additional

Published
1995
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results